Medicinal Products

Dáil Éireann Debate, Wednesday - 6 May 2026

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Wednesday, 6 May 2026

Questions (1125)

Ken O'Flynn

Question:

1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]

Written answers

Minister for Health

As this is a service matter, I have asked the Health Service Executive to respond to the Deputy as soon as possible.

Question No. 1126 answered with Question No. 838.

Question No. 1127 answered with Question No. 838.

Question No. 1128 answered with Question No. 838.

• Previous Answer
• Next Answer